Xeris Biopharma Holdings (XERS) Equity Average (2020 - 2026)

Xeris Biopharma Holdings has reported Equity Average for 7 years, with the latest figure at $13.4 million in Q1 2026.

• For the quarter ending Q1 2026, Equity Average rose 141.24% year-over-year to $13.4 million; the trailing twelve-month figure through Mar 2026 stood at $13.4 million (up 141.24% YoY), and the FY2025 full-year result was -$8.0 million, up 56.24% from the prior year.
• Equity Average for Q1 2026 stood at $13.4 million, up from $6.4 million in the prior quarter.
• The five-year high for Equity Average was $95.8 million in Q1 2022, with the low at -$32.4 million in Q1 2025.
• Historically, Equity Average has averaged $14.0 million across 5 years, with a median of $6.4 million in 2025.
• Annual changes were most pronounced in 2022 — Equity Average surged 640.13% — and 2024, when it slumped 1886.22%.
• Xeris Biopharma Holdings' Equity Average stood at $50.1 million in 2022, then tumbled by 102.91% to -$1.5 million in 2023, then tumbled by 1886.22% to -$29.0 million in 2024, then soared by 122.14% to $6.4 million in 2025, then soared by 108.14% to $13.4 million in 2026.
• The last three Equity Average figures came in at $13.4 million (Q1 2026), $6.4 million (Q4 2025), and -$10.1 million (Q3 2025), per Business Quant data.